TABLE 1.
Characteristics of the study populationa
| Characteristic | Value for:
|
P value | |
|---|---|---|---|
| Sarcoidosis patients | Disease controls | ||
| No. of: | |||
| Patients (total) | 44 | 27 | NS |
| Females/males | 19/25 | 11/16 | NS |
| African-Americans, Caucasians, and Caucasian/Hispanics | 15, 28, 1 | 4, 23 | NS |
| Patients at stage 0/1/2/3/4 | 0/11/25/5/3 | ND | |
| Patients with IS at bronchoscopy | 13 | 5 | |
| Patients with response to ESAT-6 or KatG/total no. | |||
| CD4+ | 32/44 | 1/27 | 0.00005 |
| CD8+ | 25/41 | 1/26 | 0.0003 |
| Median yr of age (min, max) | 45 (21, 80) | 60 (28, 79) | 0.0009 |
| Median % Lym (min, max) | 17 (1, 66) | 6 (1, 85) | NS |
a
Comparison between the two groups for sex, age, and race were assessed using the Wilcoxon rank sum test. Fisher's exact test was used to compare CD4+ and CD8+ responders across the two groups. The CD4+ or CD8+ response was defined as positive when the frequency of recognition was at least twice background fluorescence and greater than 0.5%. min, minimum; max, maximum; IS, immunosuppression; Lym, lymphocyte; ND, not done; NS, not significant.